Research programme: T cell engagers - Ab Studio/Candid Therapeutics
Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Ab Studio; Candid Therapeutics
- Class Bispecific antibodies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders